The nation of Zimbabwe has declined a significant American healthcare agreement worth $367m (£272m) over five years because of Washington's insistence on sensitive data.
The decision was revealed following a official document from December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "lopsided".
An official representative has since stated that the US was requesting biological samples for research and profit but was unwilling to share the benefits from future vaccines.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more dialogue to find a deal acceptable to both sides so the country's vital HIV programme can proceed.
Wider Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to enhance openness and responsibility.
According to reports, Sixteen African countries have so far agreed to these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be accessible to our people if a future pandemic arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending frameworks previously set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This mechanism is designed to ensure that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent co-operation might be arranged in a way that honours the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks need to persist considering a large portion of the country's Aids initiatives depended on external financing.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.
The halted deal underscores the complex tensions between accepting vital international aid and protecting a country's data in an increasingly data-driven world.